Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entospletinib or placebo plus intensive chemotherapy for newly diagnosed NPM1-mutated acute myeloid leukemia
MOH_2022-01-24_010262Phase 3Not yet recruiting
- Sponsor
- Kronos Bio, Inc.
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Entospletinib + intensive chemotherapy with Placebo + intensive chemotherapy (2 arms). Planned start Jan 2022; status: not yet recruiting.
02
Drugs
entospletinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-01-24_010262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-24_010262.